CM
RCKT icon

Caption Management’s Rocket Pharmaceuticals RCKT Stock Holding History

Caption Management’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,200
Closed -$25K – 1975
2025
Q2 		$25K Hold
10,200
– – ﹤0.01% 1356
2025
Q1 		$68K Sell
10,200
-45,000
-82% -$445K ﹤0.01% 1378
2024
Q4 		$694K Sell
55,200
-44,800
-45% -$674K 0.01% 1007
2024
Q3 		$1.85M Buy
100,000
+40,000
+67% +$819K 0.03% 591
2024
Q2 		$1.29M Buy
60,000
+30,000
+100% +$689K 0.02% 600
2024
Q1 		$808K Hold
30,000
– – 0.01% 781
2023
Q4 		$899K Buy
30,000
+24,800
+477% +$547K 0.01% 830
2023
Q3 		$107K Buy
+5,200
New +$94.5K ﹤0.01% 1150
2023
Q1 		– Sell
-353,200
Closed -$6.91M – 1473
2022
Q4 		$6.91M Buy
353,200
+124,600
+55% +$2.29M 0.11% 233
2022
Q3 		$3.65M Buy
+228,600
New +$3.57M 0.05% 444
2021
Q3 		– Sell
-30,300
Closed -$1.34M – 1749
2021
Q2 		$1.34M Buy
+30,300
New +$1.32M 0.02% 814

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Caption Management's RCKT Position: Q1 2025 in Review

Caption Management sold out of Rocket Pharmaceuticals (RCKT) in Q1 2025, closing a stake of 681 shares — an estimated $6.73K sold.

Caption Management first reported a position in RCKT in Q4 2022 and held it in 3 quarters. The position peaked at $2.54M in Q4 2022. 236 funds tracked by Wall St. Rank hold RCKT as of Q1 2025.

  • Caption Management reported no remaining Rocket Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Caption Management sold 681 Rocket Pharmaceuticals shares in Q1 2025, an estimated $6.73K.
  • Caption Management first reported a position in Rocket Pharmaceuticals in Q4 2022 and held it in 3 quarters.
  • Caption Management's Rocket Pharmaceuticals position peaked at $2.54M in Q4 2022.
  • 236 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2025.

Based on Caption Management's 13F filing for Q1 2025, filed 15 May 2025.